Epigenetic Reprogramming of Drug Resistance in DLBCL
Last updated March 16, 2018
Developed by
Hautaniemi Lab
Visualization of
Individual images
Images by day
Images by cell line
Pretreatment compound
Azacitidine
Decitabine
Epigallocatechin
Lomeguatrib
Procainamide
RG108
Thioguanine
C646
AR-42
Belinostat
CI994
CUDC-101
CUDC-907
Entinostat
Givinostat
JNJ-26481585
Mocetinostat
PCI-24781
PCI-34051
Panobinostat
RGFP966
Resminostat
Rocilinostat
Romidepsin
SB939
Tubacin
Tubastatin A
Valproic acid
Vorinostat
(R)-PFI-2
A-366
EPZ005687
EPZ5676
GSK343
GSK591
LLY-507
MS023
MS049
SGC0946
SGC707
Tazemetostat
UNC0638
UNC0642
UNC1999
GSK J4 HCl
IOX-1
Tranylcypromine
BAZ2- ICR
GSK2801
I-BET151
JQ1
LP-99
NI-57
NVS-1
OF-1
OTX015
PFI-1
PFI-4
SGC-CBP30
UNC1215
Rifampicin
Suramin
Previous
Next
Visualization of
Individual images
All cell lines
Pretreatment compound
Belinostat
Entinostat
Givinostat
Resminostat
Vorinostat
EPZ5676
SGC0946
Tazemetostat
I-BET151
OTX015
Plot
Dose response curves
3D plots
Cell lines to include (select at least one)
Oci-Li-19
Oci-Ly-3
Riva-I
Su-Dhl-4
Treatment (select at least one)
Untreated RNA
Belinostat (HDACi)
Entinostat (HDACi)
Vorinostat (HDACi)
Tazemetostat (HMTi)
Select genes of insterest
ABC-GCB subtyping
Immune cells' lineage
Doxorubicin related genes
Rituximab related genes
CD20 regulators
Apoptosis
TNF and TNF-receptor superfamilies
DNA repair
Homologous recombination
Non-homologous end joining
Cell cycle
G1 arrest during cell cycle
ADME genes
Core ADME genes
Epigenetically regulated ADME genes
Epigenetic Enzymes
DNMTs
BRDs
HATs
HDACs
HDMs
HMTs
Belinostat target genes
Doxorubicin target genes
Entinostat target genes
Givinostat target genes
I-BET151 target genes
OTX-015 (Birabresib) target genes
Pinometostat (EPZ5676) target genes
Resminostat target genes
Rituximab target genes
SGC0946 target genes
Vorinostat target genes
Tazemetostat (EPZ6438) target genes
Insert gene list
Expression
Normalized log2 counts
Log2 fold change (from counts)
Log2 fold change (binary)
Log2 fpkm
Z-score
MAD filtering
Additional Information
DLBCL Subtype
Response to pretreatment
Cell line
Pretreatment
Plot Expression
Cell lines to include (select at least one)
Oci-Ly-19
Oci-Ly-3
Riva-I
Su-DhlL-4
Mutation Origin
Somatic
Germline
Select genes of insterest
ABC-GCB subtyping
Immune cells' lineage
Doxorubicin related genes
Rituximab related genes
CD20 regulators
Apoptosis
TNF and TNF-receptor superfamilies
DNA repair
Homologous recombination
Non-homologous end joining
Cell cycle
G1 arrest during cell cycle
ADME genes
Core ADME genes
Epigenetically regulated ADME genes
Epigenetic Enzymes
DNMTs
BRDs
HATs
HDACs
HDMs
HMTs
Belinostat target genes
Doxorubicin target genes
Entinostat target genes
Givinostat target genes
I-BET151 target genes
OTX-015 (Birabresib) target genes
Pinometostat (EPZ5676) target genes
Resminostat target genes
Rituximab target genes
SGC0946 target genes
Vorinostat target genes
Tazemetostat (EPZ6438) target genes
Insert gene list
Value to be visualized
Allele Frequency (AF)
CADD score
Plot Mutations
Cell line
Oci-Ly-19
Oci-Ly-3
Riva-I
Su-DhlL-4
Marker
53BP1 (non-homologous end joining)
cCasp3 (apoptosis)
RAD51 (homologous recombination)
Treatment
Baseline
Belinostat (HDACi)
Entinostat (HDACi)
Vorinostat (HDACi)
Tazemetostat (HMTi)
Doxorubicin
No Doxorubicin
After 4h
After 24h
Reprogramming Screening
Synergy Investigation
Gene Expression
Mutations
Immunofluorescence
Loading...
Loading...
